Clinical Trial Update: DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating DAPAgliflozine to attenuate cardiac remodeling after acute myocardial infarction is currently recruiting. The study, sponsored…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Left Ventricular Dysfunction
• Myocardial Infarction
• Non-st-elevation Myocardial Infarction
• St-elevation Myocardial Infarction

Drugs mentioned

• DAPAgliflozine (dapagliflozin)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: AMI, STEMI | Phase 3 | Status: RECRUITING